Company Overview of Transave LLC
Transave LLC develops inhaled pharmaceuticals for the site-specific treatment of lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. The company’s liposomal technology allows the release of drug in the lung's microenvironment. Its products also include Arikace for the treatment of gram-negative lung infections and pseudomonas infections in cystic fibrosis patients; and cisplatin lipid complex for the treatment of cancers affecting the lungs. Transave LLC was founded in 1997 and is headquartered in Monmouth Junction, New Jersey. As of December 1, 2010, Transave LLC operates as a subsidiary of Insmed Incorporated.
11 Deer Park Drive
Monmouth Junction, NJ 08852
Founded in 1997
Key Executives for Transave LLC
Similar Private Companies By Industry
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
|7 Oaks Pharmaceutical Corp.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Transave LLC, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.